Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

PERSEUS 2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach

Coordinator
Consiglio Nazionale Delle Ricerche, Italy
Runs
1 March 2023 to 30 September 2027
Status
Running
EU funding
€2.7m
Total cost
€2.7m
Partners
8 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101099423

What the project is doing

In the project's own words, from its summary on CORDIS.

PERSEUS intends to implement a novel nanotechnology-based cancer therapy for deep-seated clinically unmanageable, drug-resistant and metastatic tumours. Practical use of nanotechnology in clinical cancer care is still in its infancy with a full potential yet to be realized. The therapy is based on a novel nano-system (NS) made of multifunctional 2D layered nanocrystals. The NS enables, under activation by computed tomography (CT), an effective multimodal therapy with minimal or no adverse effects.

This novel paradigm uses CT not to eradicate cancer, but to trigger and to image the NS that locally activates non-mutagenic oncotherapies. The therapies delivered are excited by the conversion of low energy X-rays (i.e., CT) into heat, reactive oxygen species and radiosensitizing agents. X-ray irradiation can also induce immunogenic cell death with the exposure or release of neo-antigens to trigger an anti-cancer immune response.

The use of X-rays makes it possible to reach deep-seated tumours that are inaccessible by visible or near-infrared light-based therapies. In other words, CT is the spark that lights the match. This is a radical vision for an ambitious and high-risk project. The current proposal targets a range of cancer types including metastatic triple negative breast cancer, hepatocellular carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma.

The NS is biocompatible and also totally inactive in absence of CT radiation, i.e. the NS becomes active only where the CT beam is delivered so minimizing side effects at distal sites. The therapy is agnostic to the type of cancer and to gender incidence because it doesn't affect the body biochemistry. This is a second change of paradigm. PERSEUS vision is pursued by a multidisciplinary team composed of physicists, chemists, chemical engineers, biologists, physicians, pharmacologists and radiologists working together to develop an innovative nanotechnological approach to address unmet clinical needs.

Topics

Who is involved

OrganisationCityCountryRole
Consiglio Nazionale Delle RicercheRomaItalyCoordinator
Universidad De VigoVigo PontevedraSpainParticipant
Hun-Ren Wigner Fizikai KutatokozpontBudapestHungaryParticipant
HUN-REN Wigner Fizikai KutatokozpontBudapestHungaryParticipant
Technion - Israel Institute of TechnologyHaifaIsraelParticipant
Bedimensional SpAGenovaItalyParticipant
Karolinska InstitutetStockholmSwedenParticipant
Qed Film & Stage Productions LtdBristolUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI